For instance, in acute myeloid leukemia (AML), TP53-mutated patients exhibit complex karyotypes and a dismal median survival of <6 months, necessitating first-line therapies distinct from conventional chemotherapy (e.g., hypomethylating agents or targeted drugs) 2. This evidence concerns the gene TP53 and acute myeloid leukemia.